Concomitant Bladder Tumor Is a Risk Factor for Bladder Recurrence but Not Upper Tract.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
28 11 2022
Historique:
received: 18 10 2022
revised: 17 11 2022
accepted: 23 11 2022
entrez: 22 12 2022
pubmed: 23 12 2022
medline: 27 12 2022
Statut: epublish

Résumé

To evaluate the clinical outcomes of UTUC patients with or without concurrent bladder tumor. The Clinical Research Office of the Endourology Society-Urothelial Carcinomas of the Upper Tract (CROES-UTUC) Registry included 1134 UTUC patients with or without concurrent bladder tumor treated between 2014 and 2019. In 218 (19.2%) cases, concurrent bladder tumor was present, while in 916 (80.8%) patients, no bladder cancer was found. In the multivariable Cox regression analysis, concomitant bladder tumor (hazard ratio (HR) 1.562, 95% confidence interval (CI) 0.954-2.560, The presence of concomitant bladder tumor does not increase risk of UTUC recurrence, but it results in an increased risk of bladder recurrence. KSS does not affect bladder recurrence and can still be considered in patients with concomitant bladder tumor.

Identifiants

pubmed: 36547141
pii: curroncol29120727
doi: 10.3390/curroncol29120727
pmc: PMC9776685
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9284-9293

Références

World J Urol. 2017 Mar;35(3):337-353
pubmed: 27101100
Eur Urol. 2016 Dec;70(6):1052-1068
pubmed: 27477528
Urol Oncol. 2014 Jan;32(1):23.e1-8
pubmed: 23403206
Transl Androl Urol. 2021 Dec;10(12):4365-4375
pubmed: 35070818
Eur Urol. 2012 Feb;61(2):245-53
pubmed: 21975249
J Urol. 2019 Dec;202(6):1127-1135
pubmed: 31251717
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Rev Urol. 2022 May;19(5):280-294
pubmed: 35361927
Transl Androl Urol. 2021 Oct;10(10):4036-4050
pubmed: 34804846
Am J Surg Pathol. 2004 Dec;28(12):1545-52
pubmed: 15577672
Can Urol Assoc J. 2022 Jul;16(7):E363-E369
pubmed: 35230936
World J Urol. 2013 Feb;31(1):141-5
pubmed: 22552732
World J Urol. 2017 Mar;35(3):379-387
pubmed: 27604375
Curr Opin Urol. 2021 Jul 1;31(4):354-362
pubmed: 34009177
BJU Int. 2009 Nov;104(10):1436-40
pubmed: 19689473
Urology. 1998 Oct;52(4):594-601
pubmed: 9763077
Urol Oncol. 2018 Mar;36(3):88.e11-88.e18
pubmed: 29174945
Scand J Urol. 2022 Apr;56(2):137-146
pubmed: 35225148
JMIR Res Protoc. 2020 Jan 24;9(1):e15363
pubmed: 32012106
Urol Oncol. 2013 Nov;31(8):1615-20
pubmed: 22521771

Auteurs

Kang Liu (K)

S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong 999077, China.

Hongda Zhao (H)

S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong 999077, China.

Mario Alvarez-Maestro (M)

Department of Urology, La Paz University Hospital, 28001 Madrid, Spain.

Stavros Gravas (S)

Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, 41001 Larissa, Greece.

Koen Van Renterghem (K)

Department of Urology, Jessa Hospital University of Hasselt, 3500 Hasselt, Belgium.

Guohua Zeng (G)

Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, China.

Chi-Fai Ng (CF)

S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong 999077, China.

Pilar Laguna (P)

Department of Urology, Medipol Mega University Hospital, Istanbul Medipol University, Istanbul 34000, Turkey.

Jeremy Yuen-Chun Teoh (JY)

S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong 999077, China.

Jean De La Rosette (J)

Department of Urology, Medipol Mega University Hospital, Istanbul Medipol University, Istanbul 34000, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH